Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016263 · ClinicalTrials.gov registry record · Phase 3
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
A Phase 3 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00016263: Completed Phase 3 study, sponsored by Genta Incorporated.
NCT00016263 is a Phase 3 study that has completed, run by Genta Incorporated. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016263, a Phase 3 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more effective with or without oblimersen (G3139). PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without oblimersen (G3139) in treating patients who have advanced malignant melanoma.
Interventions
- DRUG dacarbazine
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00016263 record still lists
NCT00016263 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which dacarbazine is the first listed.
NCT00016263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016263 about?
NCT00016263 is a clinical study titled "Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more effective with or withou...
What is the current status of trial NCT00016263?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00016263?
The interventions under investigation include: dacarbazine (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016263?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia